Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0P7SO
|
||||
Former ID |
DIB011423
|
||||
Drug Name |
ADMVA
|
||||
Synonyms |
RMVA vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankara vaccine (HIV-1), ADARC; Recombinant modified vaccinia Ankaravaccine (HIV-1), Aaron Diamond AIDS Research Center; DNA vaccine (gag, pol, env, tat, nef), ADARC; DNA vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center; HIV-1 vaccine (gag, pol, env, tat, nef), ADARC; HIV-1 vaccine (gag, pol, env, tat, nef), Aaron Diamond AIDS Research Center
|
||||
Drug Type |
Vaccine
|
||||
Company |
Aaron Diamond AIDS Research Center
|
||||
Target and Pathway | |||||
Target(s) | Aldose reductase | Target Info | [543707] | ||
NetPath Pathway | IL1 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | |||||
References | |||||
Ref 521758 | ClinicalTrials.gov (NCT00252148) Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults. U.S. National Institutes of Health. | ||||
Ref 530668 | Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8816. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.